Rpharmy Honored With Family Business Award From Austin Business Journal
Austin-Based Healthcare Technology Provider Recognized for Community Impact, Life-Saving Solutions that Protect…
Oncotelic Therapeutics and Brush and Key Foundation Announce Publication in International Journal of Molecular Sciences Highlighting Context-Dependent Biomarkers in Liver and Pancreatic Cancer
AGOURA HILLS, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
Springer Nature honours Indian editors at Journal Development Symposium 2025. Brings Together Leading Editors and Publishing Experts to Shape the Future of Research Integrity and AI in Scholarly Communication
NEW DELHI, Oct. 31, 2025 /PRNewswire/ -- The day long Journal Development…
SpringWorks Therapeutics Announces Publication of Long-Term Efficacy and Safety Data from the Phase 3 DeFi Trial of OGSIVEO (nirogacestat) in Adults with Desmoid Tumors in the Journal of Clinical Oncology
Long-term continuous OGSIVEO treatment for up to 4 years was associated with…
DB-OTO Results in theNew England Journal of Medicine Showcase Dramatic and Sustained Improvements in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss
Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including…
GameChange Solar Featured in The Wall Street Journal on Saudi Arabia’s Solar Expansion
NORWALK, Conn., Sept. 22, 2025 /PRNewswire/ -- The Wall Street Journal recently featured…
AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE…
CATL and Springer Nature launch journal Watt to connect science and industry
HONG KONG, Sept. 19, 2025 /PRNewswire/ -- 21C Lab, the cutting-edge innovation…
Landmark Trial Demonstrates Efficacy of Microcurrent Therapy in Heart Failure: C-MIC II Results Published in the European Journal of Heart Failure
ZUG, Switzerland, July 23, 2025 /PRNewswire/ -- Berlin Heals and the C-MIC II…
Novo Nordisk A/S: CagriSema 2.4 mg / 2.4 mg demonstrated 22.7% mean weight reduction in adults with overweight or obesity in REDEFINE 1, published in New England Journal of Medicine
Data presented simultaneously at the American Diabetes Association’s® 85th Scientific Sessions, showed…
